Encision Reports Q2 Fiscal 2026 Results with Revenue Decline

Encision Inc., a medical device company based in Boulder, CO, reported its financial results for the second quarter of fiscal year 2026, which concluded on September 30, 2025. The company generated total net revenue of $1.52 million, a decline from the $1.76 million reported in the same quarter of the previous year. This decrease is attributed primarily to lower product and service revenues.

In detail, Encision’s product net revenue was $1.48 million, while service revenue amounted to $46 thousand. This resulted in a net loss of $268 thousand, or $(0.02) per diluted share. In comparison, during the second quarter of fiscal 2025, the company recorded product net revenue of $1.65 million and service revenue of $102 thousand, leading to a net loss of $170 thousand, or $(0.01) per diluted share.

Financial Performance Overview

The gross margin on product net revenue for the most recent quarter was 46%, a slight decrease from 47% in the same quarter last year. The decline in revenue and subsequent loss highlight ongoing challenges for the company as it navigates the competitive landscape of the medical device industry.

Encision, known for its patented Active Electrode Monitoring (AEM®) technology, aims to enhance the safety of minimally invasive surgeries by preventing dangerous radiant energy burns. Despite the recent financial setbacks, the company remains focused on its core mission of improving surgical outcomes.

Investors and stakeholders will be closely monitoring Encision’s strategies moving forward as it seeks to recover from this quarterly loss and stabilize its revenue streams. The results reflect not only the broader trends within the medical device market but also the specific hurdles that Encision faces in maintaining its growth trajectory.

As the company prepares for the upcoming quarters, it will be crucial to implement effective measures to drive sales and regain investor confidence.